ProfileGDS5678 / 1450652_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 89% 94% 93% 93% 93% 93% 96% 95% 93% 93% 92% 94% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.9159493
GSM967853U87-EV human glioblastoma xenograft - Control 27.1339989
GSM967854U87-EV human glioblastoma xenograft - Control 38.1576794
GSM967855U87-EV human glioblastoma xenograft - Control 48.1058493
GSM967856U87-EV human glioblastoma xenograft - Control 58.0487393
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.5891393
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.7539393
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.7665196
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.4759395
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.980993
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.7232593
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.6737992
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.0568294
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.2537190